Evidence map›Paper›PMID 32901098›Full record

ArticleScientific reports2020

Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025.

Xiling Lin, Yufeng Xu, Xiaowen Pan, Jingya Xu, Yue Ding, Xue Sun, Xiaoxiao Song, Yuezhong Ren, Peng-Fei Shan

3 registry-linked trialsAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 869 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
869citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05556291 completednot on this mapstarted 2022, after this paper: background citation

Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus

TypeobservationalSponsorGetz PharmaRan2022 to 2024Enrolled190ConditionsEfficacy, Safety, TolerabilityArmsCombinations of Oral Blood Glucose Lowering Drugs
NCT06518486 nacompletednot on this mapstarted 2024, after this paper: background citation

The Effectiveness of Foot-Ankle Exercise and Walking Exercise on Foot Neuropathy, Stress, Quality of Life, Blood Sugar Markers, Blood Pressure, Ankle-Brachial Index, and BMI Among Diabetes Mellitus Patients

TypeinterventionalSponsorTaipei Medical UniversityRan2024 to 2025Enrolled375ConditionsDiabetic Foot, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Diabetes Type 2ArmsFoot-ankle exercise, Walking exercise, Usual care and health education
NCT07270328 nacompletednot on this mapstarted 2024, after this paper: background citation

A Pilot Study of Feasibility and Exploratory Study for a Definitive Randomised Controlled Trial of Foot-Ankle Versus Walking Exercises in Patients With Diabetes Mellitus: Effects on Neuropathy, Stress, and Quality of Life

TypeinterventionalSponsorTaipei Medical UniversityRan2024 to 2024Enrolled108ConditionsDiabete Mellitus, Diabete Type 2, Diabetic Peripheral Neuropathy, Diabetic FootArmsFoot-ankle exercise group, Walking exercise group, Control group
3 · Its place in the literature

Who cites it

869 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Effects ofGut microbes · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

809 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiling Lin *Department of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Yufeng Xu *Department of Ophthalmology, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Xiaowen Pan *Department of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Jingya XuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Yue DingDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Xue SunDepartment of General Practice, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Xiaoxiao SongDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Yuezhong RenDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Peng-Fei ShanDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of ZheJiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China. pengfeishan@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is a leading cause of mortality and reduced life expectancy. We aim to estimate the burden of diabetes by type, year, regions, and socioeconomic status in 195 countries and territories over the past 28 years, which provide information to achieve the goal of World Health Organization Global Action Plan for the Prevention and Control of Noncommunicable Diseases in 2025. Data were obtained from the Global Burden of Disease Study 2017. Overall, the global burden of diabetes had increased significantly since 1990. Both the trend and magnitude of diabetes related diseases burden varied substantially across regions and countries. In 2017, global incidence, prevalence, death, and disability-adjusted life-years (DALYs) associated with diabetes were 22.9 million, 476.0 million, 1.37 million, and 67.9 million, with a projection to 26.6 million, 570.9 million, 1.59 million, and 79.3 million in 2025, respectively. The trend of global type 2 diabetes burden was similar to that of total diabetes (including type 1 diabetes and type 2 diabetes), while global age-standardized rate of mortality and DALYs for type 1 diabetes declined. Globally, metabolic risks (high BMI) and behavioral factors (inappropriate diet, smoking, and low physical activity) contributed the most attributable death and DALYs of diabetes. These estimations could be useful in policy-making, priority setting, and resource allocation in diabetes prevention and treatment.

Indexed as

Global HealthLife ExpectancyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Global Burden of DiseaseHumansIncidenceInternational AgenciesMortalityPrognosisQuality-Adjusted Life YearsRisk AssessmentRisk FactorsSurvival Rate

Identifiers

PMID32901098
PMCPMC7478957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.